Use of Counter-balanced Smith Machine Affects Performance Measurements for Rebound Bench Press Throws

Rebound bench presses throws (RBT), often performed on a Smith machine, are used for assessment and training of upper body power. During a RBT, the stretch-shortening cycle potentiates performance in the concentric movement. Smith machines frequently utilize a counter-balance weight to reduce the net load on the barbell; however, the use of counter-balance weight affects measures of performance for RBT. PURPOSE: To evaluate how the use of a counter-balanced Smith machine affects performance measures for RBT. METHODS: Performance measures for the no counter-balanced (NCB) and counter-balanced (CB) RBT were assessed for 24 men (age: 23 ± 3 years, height: 179 ± 6 cm, mass: 91 ± 17 kg, bench press 1-repetition maximum [1RM]: 107 ± 18 kg). Each participant performed 2 sets of 2 repetitions of RBT for each condition at 30 % of their 1RM. Peak power, peak force, peak concentric and eccentric velocities, and duration of eccentric and concentric phases were measured using a linear accelerometer attached to the barbell; peak ground reaction force (GRF) was measured using a force plate. For each condition, data from the repetition with the highest peak power was used in further analyses. Peak EMG was measured for the right pectoral, deltoid and triceps muscles and normalized using peak EMG in the 1RM. RESULTS: Peak barbell measurements for power (NCB: 1220 ± 269 W, CB: 1069 ± 255 W), force (NCB: 906 ± 252 N, CB: 713 ± 143 N), and concentric (NCB: 2.54 ± 0.27 m•s-1, CB: 2.24 ± 0.32 m•s-1) and eccentric (NCB: -1.19 ± 0.46 m•s-1, CB: -0.95 ± 0.29 m•s-1) velocities were significantly (p\u3c0.05) higher for NCB compared to CB. The durations for the eccentric (NCB: 0.53 ± 0.16 s, CB: 0.64 ± 0.12 s) and concentric phases (NCB: 0.58 ± 0.58 s, CB: 0.77 ± 0.82 s), and peak pectoral EMG (NCB: 91 ± 21 % of 1RM, CB: 101 ± 24 % of 1RM) were lower for NCB compared to CB. Peak EMG for deltoid and triceps and peak GRF were unaffected by the use of counter-balance weights. CONCLUSION: The use of CB equipment resulted in reduced performance measurements (peak power, peak force, and peak eccentric and concentric velocities) for the RBT compared to NCB equipment. The lower peak eccentric stretch velocity likely resulted in a less effective stretch-shortening cycle for CB compared to NCB and thus helps explain the lower performance measurements found for CB

First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models

JAK4D, a first-in-class thyrotropin-releasing hormone (TRH)-based compound, is a prospective therapeutic candidate offering a multifaceted approach to treating neurodegeneration and other CNS conditions. The purpose of these studies was to determine the ability of JAK4D to bind to TRH receptors in human brain and to evaluate its neuropharmacological effects in neurodegenerative animal models. Additionally, JAK4D brain permeation was examined in mouse, and initial toxicology was assessed in vivo and in vitro. We report that JAK4D bound selectively with nanomolar affinity to native TRH receptors in human hippocampal tissue and showed for the first time that these receptors are pharmacologically distinct from TRH receptors in human pituitary, thus revealing a new TRH receptor subtype which represents a promising neurotherapeutic target in human brain. Systemic administration of JAK4D elicited statistically significant and clinically-relevant neuroprotective effects in three established neurodegenerative animal models: JAK4D reduced cognitive deficits when administered post-insult in a kainate (KA)-induced rat model of neurodegeneration; it protected against free radical release and neuronal damage evoked by intrastriatal microdialysis of KA in rat; and it reduced motor decline, weight loss, and lumbar spinal cord neuronal loss in G93A-SOD1 transgenic Amyotrophic Lateral Sclerosis mice. Ability to cross the blood–brain barrier and a clean initial toxicology profile were also shown. In light of these findings, JAK4D is an important tool for investigating the hitherto-unidentified central TRH receptor subtype reported herein and an attractive therapeutic candidate for neurodegenerative disorders. •First-in-class TRH-based compound JAK4D detects new receptor subtype in human brain.•JAK4D elicits statistically significant effects in neurodegenerative animal models.•JAK4D crosses the blood–brain barrier and has a clean initial toxicology profile.•JAK4D is a tool to study central pharmacologically-distinct TRH receptor subtype.•JAK4D is an attractive therapeutic candidate for neurodegenerative diseases